title: Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy.
abstract: OBJECTIVE
  To investigate bone metabolism in postmenopausal women with rheumatoid arthritis (RA) treated with or not treated with corticosteroids, and the response to hormone replacement therapy (HRT).
  
  
  METHODS
  One hundred six RA patients were divided into those taking low-dose steroids (RA+; n = 35) and those not (RA-; n = 71) and randomly allocated to receive HRT or calcium for 2 years. Bone formation markers included serum osteocalcin (OC) and bone-specific alkaline phosphatase, and resorption markers included urinary deoxypyridinoline (DPyr) and CrossLaps (XL). Bone mineral density (BMD) was measured annually using dual x-ray absorptiometry.
  
  
  RESULTS
  OC levels were significantly lower in both the RA+ and RA- groups compared with 112 healthy control subjects (P < 0.01 and P < 0.05, respectively), but were similar in the 2 RA groups. DPyr and XL levels were elevated in the RA+ group compared with the RA- group (P < 0.05) but were similar between the RA- group and controls. OC was negatively correlated with parameters of disease activity (P < 0.05). After HRT, XL excretion decreased significantly in the overall RA group. Three-month changes in XL correlated with 2-year changes in spinal BMD (P < 0.01).
  
  
  CONCLUSIONS
  Bone metabolism may be uncoupled in chronic RA. Bone formation appears to be reduced, partly reflecting disease activity, whereas resorption is increased only in steroid users. HRT reduces resorption in RA irrespective of steroid usage, emphasizing its value in the treatment of postmenopausal women with RA.
authors.affiliation: St. Thomas' Hospital, London, UK.
authors.forename: G M
authors.initials: GM
authors.lastname: Hall
authors.forename: T D
authors.initials: TD
authors.lastname: Spector
authors.forename: P D
authors.initials: PD
authors.lastname: Delmas
mesh_terms: D015502:Absorptiometry, Photon; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001862:Bone Resorption / Q000188:drug therapy / Q000378:metabolism; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000592:standards; D005260:Female; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use; D015675:Osteocalcin / Q000097:blood; D017698:Postmenopause / Q000378:metabolism*
chemical_list: D000305:Adrenal Cortex Hormones; D000596:Amino Acids; D015415:Biomarkers; D015675:Osteocalcin; D004958:Estradiol; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase; D002118:Calcium; D009640:Norethindrone